Urology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The Sparc trial
Journal of Clinical Oncology, 10/08/09

Sternberg CN et al. – Oral satraplatin delayed progression of disease and pain in patients with metastatic CRPC experiencing progression after initial chemotherapy but did not provide a significant OS benefit. Satraplatin was generally well tolerated. These results suggest activity for satraplatin in patients with CRPC who experience progression after initial chemotherapy.

Methods

950 patients
Randomly assigned (2:1) to receive oral satraplatin (n = 635) 80 mg/m2 on days 1 to 5 of 35-day cycle and prednisone 5 mg BID or placebo (n = 315) and prednisone 5 mg BID.
Primary end points were PFS and OS
Secondary end point was time to pain progression (TPP)

Results

33% reduction (hazard ratio [HR] = 0.67; 95% CI, 0.57 to 0.77) observed in risk of progression or death with satraplatin versus placebo
Effect maintained irrespective of prior docetaxel treatment
No difference in OS seen between the satraplatin and placebo arms
Compared with placebo, satraplatin significantly reduced TPP
Satraplatin generally well tolerated, although myelosuppression and GI disorders occurred more frequently with satraplatin

<< Previous
Out-of-Pocket Health Care Costs Could Increase More Than 35...

Next >>
Characteristics of Candida albicans Biofilms Grown in a Synthetic...